Global Cancer Tissue Diagnostics Market Size By Type of Disease, By Final User, By Application, By Geographic Scope And Forecast
Published on: 2024-08-08 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Cancer Tissue Diagnostics Market Size By Type of Disease, By Final User, By Application, By Geographic Scope And Forecast
Cancer Tissue Diagnostics Market Size And Forecast
Cancer Tissue Diagnostics Market size was valued at USD 56.71 Billion in 2023 and is projected to reach USD 83.27 Billion by 2030, growing at a CAGR of 9.4% during the forecast period 2024-2030.
Global Cancer Tissue Diagnostics Market Drivers
The growth and development of the Cancer Tissue Diagnostics Market is attributed to certain main market drivers. These factors have a big impact on how Cancer Tissue Diagnostics are demanded and adopted in different sectors. Several of the major market forces are as follows
- Growing Cancer prevalence and Prevalence One major factor driving the need for cancer tissue diagnostics is the increased prevalence of different types of cancer worldwide. Accurate and timely diagnostic techniques are in more demand as cancer rates rise.
- Developments in Diagnostic Technologies As a result of ongoing improvements in the sensitivity, specificity, and accuracy of cancer tissue diagnostics, the market is expected to grow. Examples of these technologies include immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), and molecular diagnostics.
- Rise of Personalized Medicine By identifying certain biomarkers, genetic mutations, and molecular profiles in tumors, cancer tissue diagnostics contribute significantly to personalized medicine. This helps pick focused therapies, which in turn drives market demand.
- Growing Stress on Early Detection A cancer patient’s prognosis depends heavily on early detection. Diagnostics using cancer tissue can identify tumors accurately and early, which improves prognosis and treatment options.
- Rise in Biopsy operations The need for effective and precise tissue diagnostic tools and assays is driven by the rising number of biopsy operations carried out for cancer diagnosis and treatment monitoring.
- Growing Elderly Population The incidence of cancer tends to rise with global population aging. The need for cancer tissue diagnostics is increasing due in part to the aging population, especially for age-related malignancies.
- Raising Awareness and Screenings People are prompted to conduct diagnostic tests by government initiatives, coordinated screening programs, and enhanced awareness campaigns for various malignancies. This is driving up demand for tissue diagnostics.
- Technological Advancements in Biomarker Discovery To increase the uptake of cancer tissue diagnostics, ongoing research and development projects concentrate on finding novel biomarkers and targets linked to certain tumors.
- Growing Healthcare Expenditure The market for cancer tissue diagnostics is expected to rise as a result of the increased expenditure in healthcare infrastructure, especially in emerging economies where access to cutting-edge diagnostic methods is improved.
- Demand for Companion Diagnostics The adoption of cancer tissue diagnostics in conjunction with targeted therapies is driven by the need for companion diagnostics, which allow the best course of treatment to be chosen for a patient’s unique genetic composition.
Global Cancer Tissue Diagnostics Market Restraints
The Cancer Tissue Diagnostics Market has a lot of room to grow, but there are several industry limitations that could make it harder for it to do so. It’s imperative that industry stakeholders comprehend these difficulties. Among the significant market limitations are
- Exorbitant Cost of Diagnostic Tests Modern cancer tissue diagnostic techniques, such as sequencing technologies and molecular testing, are frequently associated with exorbitant costs, which restrict patient and healthcare facility accessibility and affordability.
- Regulatory and Reimbursement Difficulties Tight regulatory approval procedures and complicated reimbursement procedures for innovative diagnostic tests can impede market expansion and postpone the release and uptake of new diagnostic technologies.
- Restricted Access to Advanced Healthcare The adoption of sophisticated cancer tissue diagnostic technologies is hampered by unequal access to advanced healthcare facilities, particularly in rural or developing areas. This creates market barriers.
- Biomarker Identification Challenges Finding distinct and clinically relevant biomarkers for every form of cancer is a difficult task that restricts the creation of diagnostic tests aimed at uncommon or less prevalent cancers.
- Interpretation and Standardization Problems Adoption of cancer tissue diagnostics may be impacted by discrepancies in the interpretation and standardization of test results throughout laboratories or diagnostic platforms.
- Technology Limitations Despite developments, some technology constraints in diagnostic instruments’ sensitivity, specificity, and detection thresholds can hinder their accuracy in analyzing cancer tissue, which could hinder market growth.
- Ethical and Privacy Issues Questions about the appropriate use of patient tissue samples, data privacy, and informed consent for genetic testing in the diagnosis of cancer may create moral conundrums and restrict the growth of the market.
- Complexity of Data Analysis There may be difficulties in analyzing, interpreting, and integrating massive amounts of complicated data produced by cutting-edge diagnostic methods like next-generation sequencing (NGS) into clinical practice.
- Training and Infrastructure Gaps The expansion of the market may be hampered by inadequate training and a shortage of qualified personnel who can operate and interpret the findings of complex cancer tissue testing equipment.
- COVID-19 Impact The COVID-19 pandemic that is still running strong has caused delays in cancer diagnosis, treatment, and research. As a result, the use and expansion of cancer tissue diagnostics have been impacted.
Global Cancer Tissue Diagnostics Market Segmentation Analysis
The Global Cancer Tissue Diagnostics Market is Segmented on the basis of Type of Disease, Final User, Application, and Geography.
Cancer Tissue Diagnostics Market, By Type of Disease
- Breast Cancer Diagnostic instruments made especially for the study of breast cancer tissue.
- Lung Cancer Molecular profiling is one of the diagnostic tools for lung cancer.
- Colorectal Cancer Colorectal cancer tissue analysis-specific diagnostic solutions.
- Prostate Cancer Instruments for tissue sample analysis and diagnosis.
- Others This includes cancer diagnostics for ovarian, liver, and pancreatic cancers, among other cancer types.
Cancer Tissue Diagnostics Market, By The Final User
- Hospitals and Clinics Cancer tissue analysis is performed in these venues using diagnostic instruments.
- Diagnostic Laboratories Dedicated facilities providing diagnostic services for cancer tissue.
- Research Institutes Resources for cancer research utilized by academic and research institutes.
- Contract Research Organizations (CROs)Thease are companies that offer diagnostic services for research and clinical trials.
Cancer Tissue Diagnostics Market, By Application
- Diagnostics Instruments used to make tissue-analysis-based cancer diagnoses.
- Prognostics Determining the probable path and result of cancer by examining the properties of the tissue.
- Companion Diagnostics Instruments that support the use of tissue biomarkers to select individualized therapies.
Cancer Tissue Diagnostics Market, By Geography
- North America
- Europe, Asia-Pacific
- Latin America
- Middle East, and Africa
Key Players
The major players in the Cancer Tissue Diagnostics Market are
- Roche Holding AG (Switzerland)
- Abbott Laboratories (US)
- Thermo Fisher Scientific, Inc. (US)
- Danaher Corporation (US)
- Siemens Healthineers AG (Germany)
- Agilent Technologies, Inc. (US)
- Illumina, Inc. (US)
- PerkinElmer, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Leica Biosystems GmbH (Germany)
Report Scope
REPORT ATTRIBUTES | DETAILS |
---|---|
Study Period | 2020-2030 |
Base Year | 2023 |
Forecast Period | 2024-2030 |
Historical Period | 2020-2022 |
Unit | Value (USD Billion) |
Key Companies Profiled | Roche Holding AG (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), PerkinElmer, Inc. (US). |
Segments Covered | By Type of Disease, By The Final User, By Application, By Geography |
Customization scope | Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Top Trending Reports
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as a future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.